Prestige Inhome Care has found a long-term strategic partner
February 2024 — Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.
Established in 2005, Prestige Inhome Care is the leading in-home aged and NDIS care provider in Australia with over 1,800 clients, serviced by a team of more than 1,000 registered nurses and professional carers. Prestige provides first-class, premium care to its clientele across Victoria, NSW and Queensland, allowing them to stay in the comfort of their own home.
Our role in the transaction
Oaklins’ team in Australia acted as corporate advisor to the shareholders of Prestige, who were seeking an investment partner to provide growth capital. The team worked closely alongside Prestige through a comprehensive investor roadshow process to find the right-fit investor to support Prestige’s future growth. The transaction adds to Oaklins’ track record advising founder-owned businesses on sourcing institutional growth capital and support that will help catapult the business to another level of success.
Talk to the deal team
Related deals
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreTandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn more